Australian Clinical Labs Limited (ASX:ACL)
Australia
· Delayed Price · Currency is AUD 2.820
+0.030 (1.08%)
At close: Dec 5, 2025
Australian Clinical Labs Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2017 |
| Revenue | 741.27 | 696.37 | 697.07 | 995.6 | 646.7 | Upgrade
|
| Revenue Growth (YoY) | 6.45% | -0.10% | -29.98% | 53.95% | 31.83% | Upgrade
|
| Cost of Revenue | 470.41 | 442.37 | 445.45 | 546.98 | 390.18 | Upgrade
|
| Gross Profit | 270.86 | 254 | 251.62 | 448.62 | 256.53 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.23 | 0.23 | 0.23 | 0.23 | 0.03 | Upgrade
|
| Other Operating Expenses | 66.81 | 63.02 | 63.65 | 68.54 | 40.47 | Upgrade
|
| Operating Expenses | 202.86 | 191.45 | 186.4 | 174.64 | 128.53 | Upgrade
|
| Operating Income | 68 | 62.55 | 65.22 | 273.98 | 128 | Upgrade
|
| Interest Expense | -14.59 | -12.18 | -13.47 | -11.75 | -15.13 | Upgrade
|
| Interest & Investment Income | 0.41 | 0.5 | 0.18 | 0.05 | 0.08 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.78 | -4.86 | -0.4 | - | -18.46 | Upgrade
|
| EBT Excluding Unusual Items | 50.05 | 46.01 | 51.53 | 262.28 | 94.49 | Upgrade
|
| Merger & Restructuring Charges | -3.08 | -6.17 | -2.63 | -8.94 | - | Upgrade
|
| Other Unusual Items | - | -4.65 | -3.28 | - | -7.83 | Upgrade
|
| Pretax Income | 48.18 | 36.37 | 48.31 | 254.9 | 86.65 | Upgrade
|
| Income Tax Expense | 15.36 | 12.12 | 12.27 | 76.5 | 26.26 | Upgrade
|
| Earnings From Continuing Operations | 32.82 | 24.24 | 36.04 | 178.4 | 60.39 | Upgrade
|
| Minority Interest in Earnings | -0.39 | -0.31 | -0.14 | -0.16 | -0.02 | Upgrade
|
| Net Income | 32.43 | 23.93 | 35.9 | 178.24 | 60.37 | Upgrade
|
| Net Income to Common | 32.43 | 23.93 | 35.9 | 178.24 | 60.37 | Upgrade
|
| Net Income Growth | 35.50% | -33.33% | -79.86% | 195.24% | 46.34% | Upgrade
|
| Shares Outstanding (Basic) | 189 | 199 | 201 | 201 | 152 | Upgrade
|
| Shares Outstanding (Diluted) | 190 | 199 | 201 | 201 | 152 | Upgrade
|
| Shares Change (YoY) | -4.63% | -0.82% | -0.18% | 32.47% | 4.65% | Upgrade
|
| EPS (Basic) | 0.17 | 0.12 | 0.18 | 0.89 | 0.40 | Upgrade
|
| EPS (Diluted) | 0.17 | 0.12 | 0.18 | 0.88 | 0.40 | Upgrade
|
| EPS Growth | 42.09% | -32.77% | -79.82% | 122.88% | 39.83% | Upgrade
|
| Free Cash Flow | 174.39 | 153.09 | 136.75 | 262.84 | 144.36 | Upgrade
|
| Free Cash Flow Per Share | 0.92 | 0.77 | 0.68 | 1.30 | 0.95 | Upgrade
|
| Dividend Per Share | 0.125 | 0.120 | 0.140 | 0.530 | 0.142 | Upgrade
|
| Dividend Growth | 4.17% | -14.29% | -73.58% | 271.93% | -1.38% | Upgrade
|
| Gross Margin | 36.54% | 36.48% | 36.10% | 45.06% | 39.67% | Upgrade
|
| Operating Margin | 9.17% | 8.98% | 9.36% | 27.52% | 19.79% | Upgrade
|
| Profit Margin | 4.38% | 3.44% | 5.15% | 17.90% | 9.34% | Upgrade
|
| Free Cash Flow Margin | 23.53% | 21.98% | 19.62% | 26.40% | 22.32% | Upgrade
|
| EBITDA | 81.36 | 76.31 | 79.71 | 286.36 | 138.19 | Upgrade
|
| EBITDA Margin | 10.98% | 10.96% | 11.43% | 28.76% | 21.37% | Upgrade
|
| D&A For EBITDA | 13.35 | 13.76 | 14.49 | 12.37 | 10.19 | Upgrade
|
| EBIT | 68 | 62.55 | 65.22 | 273.98 | 128 | Upgrade
|
| EBIT Margin | 9.17% | 8.98% | 9.36% | 27.52% | 19.79% | Upgrade
|
| Effective Tax Rate | 31.88% | 33.33% | 25.39% | 30.01% | 30.31% | Upgrade
|
| Revenue as Reported | 742.49 | 697.54 | 704.76 | 997.17 | 644.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.